drugset / Trial / NCT05410041
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This study is a single arm, open and multi center exploratory clinical study to observe the safety and effectiveness of CAR NK-CD19 in participants with recurrent or refractory CD19 positive B-cell malignant tumors, and preliminarily evaluate the expansion of this product in vivo and the objective remission rate after administration.
Timeline
- Start
- 2022-05-25
- Primary completion
- 2023-04
- Completion
- 2024-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-NK-CD19 | Cell therapy | 1e+07 cells/kg | — |
| Subject | CAR-NK-CD19 | Cell therapy | 2e+07 cells/kg | — |
| Subject | CAR-NK-CD19 | Cell therapy | 3e+07 cells/kg | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |